Publications by authors named "Paul D Eve"

Claim this Profile
C
Correction: AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve, Steven J Woodhead

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737).
James D Osborne, Thomas P Matthews, Tatiana McHardy, Nicolas Proisy, Kwai-Ming J Cheung, Paul D Eve

J Med Chem· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Mike I Walton, Paul D Eve, Angela Hayes, Alan T Henley, Melanie R Valenti

Oncotarget· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors.
Michael Lainchbury, Thomas P Matthews, Tatiana McHardy, Kathy J Boxall, Michael I Walton, Paul D Eve

J Med Chem· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs.
Mike I Walton, Paul D Eve, Angela Hayes, Melanie R Valenti, Alexis K De Haven Brandon

Clin Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
Timothy A Yap, Mike I Walton, Kyla M Grimshaw, Robert H Te Poele, Paul D Eve, Steven J Woodhead

Clin Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, Melanie Valenti, Alexis de Haven Brandon, Paul D Eve

Mol Cancer Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors.
Victoria E Anderson, Michael I Walton, Paul D Eve, Katherine J Boxall, Laurent Antoni

Cancer Res· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Michael I Walton, Paul D Eve, Angela Hayes, Melanie Valenti, Alexis De Haven Brandon

Mol Cancer Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphorylation of cyclin dependent kinase 4 on tyrosine 17 is mediated by Src family kinases.
Nicholas G Martin, Peter C McAndrew, Paul D Eve, Michelle D Garrett

FEBS J· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis